99 related articles for article (PubMed ID: 25564071)
1. Deriving global quantitative tumor response parameters from 18F-FDG PET-CT scans in patients with non-Hodgkin's lymphoma.
Sampedro F; Domenech A; Escalera S; Carrió I
Nucl Med Commun; 2015 Apr; 36(4):328-33. PubMed ID: 25564071
[TBL] [Abstract][Full Text] [Related]
2. Obtaining quantitative global tumoral state indicators based on whole-body PET/CT scans: a breast cancer case study.
Sampedro F; Domenech A; Escalera S
Nucl Med Commun; 2014 Apr; 35(4):362-71. PubMed ID: 24374574
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma.
Manohar K; Mittal BR; Bhattacharya A; Malhotra P; Varma S
Nucl Med Commun; 2012 Sep; 33(9):974-81. PubMed ID: 22811258
[TBL] [Abstract][Full Text] [Related]
4. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
5. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
6. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
7. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
[TBL] [Abstract][Full Text] [Related]
8. Quantification of local tumor response to fractionated radiation therapy for non-Hodgkin lymphoma using weekly 18F-FDG PET/CT imaging.
Keller H; Goda JS; Vines DC; Lockwood G; Tsang R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):850-8. PubMed ID: 19515502
[TBL] [Abstract][Full Text] [Related]
9. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
11. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
[TBL] [Abstract][Full Text] [Related]
12. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
[TBL] [Abstract][Full Text] [Related]
13. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
16. Decreased brain FDG uptake in patients with extensive non-Hodgkin's lymphoma lesions.
Hanaoka K; Hosono M; Shimono T; Usami K; Komeya Y; Tsuchiya N; Yamazoe Y; Ishii K; Tatsumi Y; Sumita M
Ann Nucl Med; 2010 Dec; 24(10):707-11. PubMed ID: 20824395
[TBL] [Abstract][Full Text] [Related]
17. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
[TBL] [Abstract][Full Text] [Related]
18. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography.
Wu X; Kellokumpu-Lehtinen PL; Pertovaara H; Korkola P; Soimakallio S; Eskola H; Dastidar P
NMR Biomed; 2011 Dec; 24(10):1181-90. PubMed ID: 21387451
[TBL] [Abstract][Full Text] [Related]
19. SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma.
Chang CC; Cho SF; Chen YW; Tu HP; Lin CY; Chang CS
Clin Nucl Med; 2012 Aug; 37(8):e189-95. PubMed ID: 22785526
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy.
Jacene HA; Filice R; Kasecamp W; Wahl RL
J Nucl Med; 2009 Jan; 50(1):8-17. PubMed ID: 19091903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
